Wegovy and Ozempic Linked to Dramatically Lower Cancer Deaths, Study Shows

November 12, 2025 | University of California – San Diego

A groundbreaking study from the University of California, San Diego, suggests that popular weight loss and diabetes medications, including Wegovy and Ozempic, may offer significant benefits beyond managing obesity and type 2 diabetes. The study, which reviewed medical records from over 6,800 colon cancer patients, revealed that those using GLP-1 receptor agonists — the class of drugs to which both Wegovy and Ozempic belong — experienced cancer death rates dramatically lower than those who did not take these medications.

The results point to a potential breakthrough in cancer care, particularly for colon cancer patients, with the drugs showing a protective effect that researchers suggest could extend survival rates significantly. According to the study, patients who took GLP-1 medications had a mortality rate of just 15.5% within five years, compared to 37.1% among non-users.

This finding has sparked a wave of excitement in the medical community, as it could lead to new therapeutic strategies for cancer treatment — strategies that harness the benefits of drugs originally designed for weight loss and diabetes control.

The Study: Uncovering a New Cancer Treatment Potential

Led by Dr. Raphael Cuomo, an associate professor at UC San Diego School of Medicine and member of the UC San Diego Moores Cancer Center, the study utilized data from the University of California Health system’s extensive medical records. Researchers meticulously adjusted for variables such as age, body mass index (BMI), cancer severity, and other health factors to ensure the accuracy of their findings.

Even after accounting for these variables, the data showed that patients using GLP-1 drugs had a survival advantage that could not be explained by their other health conditions. The results suggest that the protective benefits of these medications might be intrinsic, independent of the patients’ lifestyle or other medical factors.

How Do GLP-1 Drugs Work?

GLP-1 receptor agonists, which include semaglutide (branded as Ozempic and Wegovy) and tirzepatide (Mounjaro), are best known for their ability to help people manage weight and blood sugar. These drugs work by mimicking the actions of a natural hormone in the body that helps regulate blood sugar levels and appetite.

However, their impact on cancer survival may be linked to more than just their ability to regulate metabolic health. Researchers believe that GLP-1 drugs may exert a powerful anti-cancer effect by reducing inflammation and enhancing insulin sensitivity — two critical factors in the progression of various cancers, including colon cancer.

Some laboratory studies have even suggested that GLP-1 receptor agonists may directly inhibit tumor growth, promote cancer cell death, and create a less supportive environment for tumor spread.

The study’s authors noted that the strongest benefit was observed in patients with obesity, whose elevated BMI often correlates with higher inflammation and greater metabolic stress, both of which can worsen cancer outcomes. By improving these underlying conditions, GLP-1 drugs may help make cancer more treatable and reduce the likelihood of fatal outcomes.

Caution and Next Steps: More Research Needed

While these findings are promising, researchers are cautious about jumping to conclusions. Dr. Cuomo emphasized that this study is observational, meaning it shows a correlation between GLP-1 drug use and lower cancer mortality, but it cannot definitively prove cause and effect.

The study’s findings underline the urgent need for clinical trials to investigate whether GLP-1 medications can indeed be used as an effective part of cancer treatment, particularly for patients with obesity-related cancers like colon cancer.

Dr. Cuomo and his team have called for further research to determine whether the observed survival benefits are directly linked to the drugs’ potential anti-cancer properties or whether they are merely a secondary effect of improving overall metabolic health.

As the medical world eagerly awaits the results of future trials, the idea that commonly prescribed medications like Wegovy and Ozempic could play a role in cancer therapy is generating considerable excitement. It could represent a new era of cancer treatment, where drugs designed for diabetes and weight management also serve to combat the deadly disease.

The Road Ahead

For now, GLP-1 drugs remain a critical part of the treatment landscape for type 2 diabetes and obesity. But with further study, they could soon become a key tool in the fight against colon cancer, helping to save more lives and transform cancer treatment strategies.

With clinical trials likely to follow, the hope is that these findings are just the beginning of a much larger shift in how we approach cancer care, bringing new hope to patients who may have otherwise faced a grim prognosis.